Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vasu Vasudevan

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Pharmaceutical Biotechnology|August 23, 2002
Formulation development of protein dosage formsMichael J Akers, Vasu Vasudevan, Mary Stickelmeyer
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitorsGuoxin Zhu, Scott E Conner, Xun Zhou, et al.
Investigational New Drugs|May 4, 2005
Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumorsJian Liang, Richard E Moore, Eric D Moher, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazolesThomas A Engler, Kelly Furness, Sushant Malhotra, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Pharmaceutical Biotechnology|August 23, 2002
Formulation development of protein dosage formsMichael J Akers, Vasu Vasudevan, Mary Stickelmeyer
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitorsGuoxin Zhu, Scott E Conner, Xun Zhou, et al.
Investigational New Drugs|May 4, 2005
Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumorsJian Liang, Richard E Moore, Eric D Moher, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2003
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazolesThomas A Engler, Kelly Furness, Sushant Malhotra, et al.
Pageof 1